Statements and Responses
Read our submitted letters to editors and responses to Amgen news.
-
05.15.2026
Amgen Statement on TAVNEOS® (avacopan) -
05.15.2026
340B Program Integrity Policy Update -
03.10.2025
Amgen Update on Patent Litigation Related to Fresenius Denosumab Biosimilar Products -
01.24.2025
Amgen Update on Patent Litigation Related to Celltrion Denosumab Biosimilar Products -
11.13.2024
Amgen Provides Statement on MariTide Phase 1 Data -
07.12.2024
Amgen Statement on IRS Notice Related to Horizon Acquisition -
04.29.2024
Amgen Update on Patent Litigation Related to Sandoz Denosumab Biosimilar Products -
03.01.2024
Update on Change Healthcare Cyberattack -
11.16.2023
LUMAKRAS® (sotorasib) Dose Comparison Study Results -
10.05.2023
Amgen Statement on FDA ODAC Meeting -
01.06.2023
Statement on FOURIER Analysis Published in BMJ Open -
08.16.2022
Statement on Drug Pricing Provisions Included in “Inflation Reduction Act” -
06.01.2022
Amgen Statement on Russia/Ukraine -
07.12.2021
Amgen Supports Industry Efforts to Address Global Access to COVID-19 Vaccines -
11.17.2020
Amgen Proudly Supports PhRMA’s New Principles on Clinical Trial Diversity -
07.20.2020
Oklahoma Health Care Authority and Amgen Enter into Value-Based Contract for Enbrel® (etanercept) -
05.07.2020
Amgen Comments On the Supreme Court of Japan Ruling
On PCSK9 Patent Infringement Litigation